[go: up one dir, main page]

WO1998013501A3 - Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales - Google Patents

Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales Download PDF

Info

Publication number
WO1998013501A3
WO1998013501A3 PCT/US1997/016718 US9716718W WO9813501A3 WO 1998013501 A3 WO1998013501 A3 WO 1998013501A3 US 9716718 W US9716718 W US 9716718W WO 9813501 A3 WO9813501 A3 WO 9813501A3
Authority
WO
WIPO (PCT)
Prior art keywords
viruses
promoter region
polymerase gene
attenuation
genomic promoter
Prior art date
Application number
PCT/US1997/016718
Other languages
English (en)
Other versions
WO1998013501A2 (fr
Inventor
Mohinderjit S Sidhu
Stephen A Udem
Joanne M Tatem
Brian R Murphy
Valerie B Randolph
Original Assignee
American Cyanamid Co
Us Health
Mohinderjit S Sidhu
Stephen A Udem
Joanne M Tatem
Brian R Murphy
Valerie B Randolph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co, Us Health, Mohinderjit S Sidhu, Stephen A Udem, Joanne M Tatem, Brian R Murphy, Valerie B Randolph filed Critical American Cyanamid Co
Priority to CA002265554A priority Critical patent/CA2265554A1/fr
Priority to EP97942613A priority patent/EP0932684A2/fr
Priority to JP10515749A priority patent/JP2000517194A/ja
Priority to BR9712138-0A priority patent/BR9712138A/pt
Priority to AU44278/97A priority patent/AU4427897A/en
Publication of WO1998013501A2 publication Critical patent/WO1998013501A2/fr
Publication of WO1998013501A3 publication Critical patent/WO1998013501A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Cette invention concerne des virus d'ARN de l'ordre des Mononegavirales qui sont isolés, produits par recombinaison, atténués, non segmentés, à sens négatif et monocaténaires, et qui présentent au moins une mutation d'atténuation dans la région promotrice 3' du génome et au moins une mutation d'atténuation dans le gène polymérase de l'ARN. On formule des vaccins avec ces virus et un support physiologiquement acceptable. Ces vaccins permettent d'immuniser un individu par induction d'une protection contre un virus monocaténaire, non segmenté et à sens négatif de l'ordre des Mononegavirales.
PCT/US1997/016718 1996-09-27 1997-09-19 Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales WO1998013501A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002265554A CA2265554A1 (fr) 1996-09-27 1997-09-19 Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales
EP97942613A EP0932684A2 (fr) 1996-09-27 1997-09-19 Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales
JP10515749A JP2000517194A (ja) 1996-09-27 1997-09-19 モノネガビラレス（Ｍｏｎｏｎｅｇａｖｉｒａｌｅｓ）と称される目のウイルスにおける弱毒化の原因となる３’ゲノムプロモーター領域およびポリメラーゼ遺伝子の突然変異
BR9712138-0A BR9712138A (pt) 1996-09-27 1997-09-19 Vìrus de rna isolado, vacina, processo para imunizr um indivìduo para induzir proteção contra um vìrus de rna não segmentado, sentido negativo, de filamento único, da ordem mononegavirales e para produzir vìrus de rna, molécula de ácido nucleico isolada e composição.
AU44278/97A AU4427897A (en) 1996-09-27 1997-09-19 3' genomic promoter region and polymerase gene mutations responsible for att enuation in viruses of the order designated mononegavirales

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2682396P 1996-09-27 1996-09-27
US60/026,823 1996-09-27

Publications (2)

Publication Number Publication Date
WO1998013501A2 WO1998013501A2 (fr) 1998-04-02
WO1998013501A3 true WO1998013501A3 (fr) 1998-08-13

Family

ID=21833976

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/016718 WO1998013501A2 (fr) 1996-09-27 1997-09-19 Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales

Country Status (8)

Country Link
EP (1) EP0932684A2 (fr)
JP (1) JP2000517194A (fr)
KR (1) KR20000048628A (fr)
CN (1) CN1232504A (fr)
AU (1) AU4427897A (fr)
BR (1) BR9712138A (fr)
CA (1) CA2265554A1 (fr)
WO (1) WO1998013501A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12391957B2 (en) 2018-08-17 2025-08-19 Icahn School Of Medicine At Mount Sinai Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887699B1 (en) 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
US6410023B1 (en) * 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
WO1999015672A1 (fr) * 1997-09-19 1999-04-01 American Cyanamid Company Virus syncytiaux respiratoires attenues
EP1064358A2 (fr) * 1998-03-26 2001-01-03 American Cyanamid Company Mutations responsables de l'attenuation du virus de la rougeole ou du virus respiratoire syncytial humain du sous-groupe b
DE69943215D1 (de) * 1998-06-03 2011-04-07 Wyeth Corp Verfahren zum retten der rna-viren
WO1999064571A1 (fr) 1998-06-12 1999-12-16 Mount Sinai School Of Medicine Of The City University Of New York Interferon induisant des virus attenues mis au point par genie genetique
SK288200B6 (sk) 1998-06-12 2014-06-03 Mount Sinai School Of Medicine Použitie geneticky skonštruovaného oslabeného vírusu chrípky na liečbu alebo prevenciu infekčného ochorenia citlivého na interferón
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
AU2001257001A1 (en) 2000-04-10 2001-10-23 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
ATE343589T1 (de) 2000-06-23 2006-11-15 Wyeth Corp Modofiziertes morbillivirus v proteine
US7361496B1 (en) 2000-08-02 2008-04-22 Wyeth Rescue of mumps virus from cDNA
CN101921732A (zh) 2001-01-19 2010-12-22 维洛诺瓦蒂夫公司 在易感哺乳动物中引起呼吸道疾病的病毒
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
JP4553588B2 (ja) 2002-02-21 2010-09-29 メディミューン，エルエルシー メタニューモウイルス（ｍｅｔａｐｎｅｕｍｏｖｉｒｕｓ）株と、ワクチン製剤でのおよび抗原配列発現用ベクターとしてのその使用
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
EP1499348B1 (fr) 2002-04-26 2014-10-01 MedImmune, LLC Methode pour la production de virus influenza b infectieux en culture cellulaire
EP2110382A1 (fr) * 2002-06-20 2009-10-21 Institut Pasteur ADNc infectieux pour une souche de vaccin améliorée du virus de la rougeole Utilisation pour compositions immunogènes
ES2427139T3 (es) 2002-06-20 2013-10-29 Institut Pasteur Virus recombinantes del sarampión que expresan epítopos de antígenos de virus de ARN y uso de los virus recombinantes para la preparación de composiciones de vacuna
CA2432738A1 (fr) * 2003-02-26 2004-08-26 Philippe Despres Nouvelles proteines des virus de la dengue et du nil et genes codant pour ces proteines, et leurs utilisations dans des vaccins et dans des applications therapeutiques et diagnostiques
AU2004226369A1 (en) 2003-03-28 2004-10-14 Medimmune, Llc Compositions and methods involving respiratory syncytial virus subgroup B strain 9320
JP2007525178A (ja) 2003-04-25 2007-09-06 メッドイミューン バクシーンズ，インコーポレイティド メタニューモウイルス株、そのワクチン製剤における用途、抗原性配列の発現のためのベクターとしての用途、並びにウイルス増殖方法
WO2005018539A2 (fr) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Hemagglutinine du virus de la grippe et variantes de la neuraminidase
JP4771959B2 (ja) 2003-12-23 2011-09-14 メディミューン，エルエルシー インフルエンザウイルス作製のための多重プラスミド系
US7527800B2 (en) 2004-05-25 2009-05-05 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
CN102727880A (zh) 2004-06-01 2012-10-17 西奈山医学院 遗传工程猪流感病毒及其应用
WO2006088481A2 (fr) 2005-02-15 2006-08-24 Mount Sinai School Of Medicine Of New York University Virus de la grippe equine genetiquement modifie et utilisations associees
ES2527503T3 (es) 2005-03-08 2015-01-26 Medimmune, Llc Virus influenza reordenantes
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
CA2613284A1 (fr) 2005-06-21 2007-01-04 Medimmune Vaccines, Inc. Procedes et compositions permettant d'exprimer un virus a arn sens negatif dans des cellules canines
ES2668464T3 (es) 2005-12-02 2018-05-18 Icahn School Of Medicine At Mount Sinai Virus quiméricos de la enfermedad de Newcastle que presentan proteínas de superficie no naturales y sus usos
AU2007240448B8 (en) 2006-04-19 2014-03-06 Medimmune Llc. Methods and compositions for expressing negative-sense viral RNA in canine cells
WO2008133701A1 (fr) 2006-07-21 2008-11-06 Medimmune, Llc. Procédés et compositions permettant d'accroître la capacité de réplication d'un virus de la grippe
EP2056872A4 (fr) 2006-08-09 2016-12-21 Medimmune Llc Variants d'hémagglutinine et de neuraminidase de la grippe
CA2673535A1 (fr) * 2006-12-22 2008-11-20 The Penn State Research Foundation Polymerases modifiees et virus attenues et leurs procedes d'utilisation
JP5666905B2 (ja) 2007-06-18 2015-02-12 メディミューン，エルエルシー ヘマグルチニンポリペプチド中に変化を有するインフルエンザｂウイルス
CA2730408A1 (fr) 2008-07-11 2010-01-14 Chin-Fen Yang Variants de l'hemagglutinine et de la neuraminidase de la grippe
CN102203122A (zh) 2008-11-05 2011-09-28 惠氏有限责任公司 用于预防β-溶血链球菌(BHS)疾病的多组分免疫原性组合物
EP2393921B1 (fr) 2009-02-05 2015-07-15 Icahn School of Medicine at Mount Sinai Virus chimériques de la maladie de newcastle et leurs utilisations
WO2010093537A2 (fr) 2009-02-12 2010-08-19 Medimmune, Llc Hémagglutinine du virus de la grippe et variants de la neuraminidase
AU2010234849B2 (en) 2009-03-30 2017-06-22 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
US9217157B2 (en) 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
WO2011014645A1 (fr) 2009-07-30 2011-02-03 Mount Sinai School Of Medicine Of New York University Virus de la grippe et leurs utilisations
MX2012011300A (es) 2010-03-30 2012-11-29 Sinai School Medicine Vacunas del virus de influenza y usos de las mismas.
EP2420242A1 (fr) 2010-08-20 2012-02-22 Lauer, Ulrich M. Virus de la rougeole oncolytique
WO2013046216A2 (fr) * 2011-06-08 2013-04-04 JOSHI Vishwas Système d'expression simple de mammifère à deux plasmides destiné à la production de protéines et de virus recombinés
CN103906843B (zh) * 2011-06-08 2016-12-07 维什瓦斯·乔希 双质粒哺乳动物表达系统
CN116162175A (zh) 2011-09-20 2023-05-26 西奈山伊坎医学院 流感病毒疫苗及其应用
ES2752190T3 (es) 2012-09-14 2020-04-03 Us Health Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso
NZ627796A (en) 2012-12-18 2017-07-28 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
US20160015760A1 (en) 2013-03-14 2016-01-21 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
WO2014159960A1 (fr) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Anticorps contre l'hémagglutinine du virus de la grippe et utilisations correspondantes
EP3110443A4 (fr) 2014-02-27 2017-11-15 Viralytics Limited Thérapie combinée pour le traitement du cancer
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
WO2016137929A1 (fr) 2015-02-26 2016-09-01 Boehringer Ingelheim Vetmedica Gmbh Vaccin contre le virus de la grippe porcine bivalent
AU2016302237B2 (en) 2015-08-03 2022-08-04 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
US10478489B2 (en) 2015-08-20 2019-11-19 University Of Rochester Live-attenuated vaccine having mutations in viral polymerase for the treatment and prevention of canine influenza virus
US10548966B2 (en) 2015-08-20 2020-02-04 University Of Rochester Single-cycle virus for the development of canine influenza vaccines
WO2017031401A2 (fr) 2015-08-20 2017-02-23 University Of Rochester Virus ns1 tronqué pour le développement de vaccins contre la grippe canine
CN109414488A (zh) 2016-06-03 2019-03-01 罗切斯特大学 马流感病毒减毒活疫苗
MX2018015755A (es) 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
EP3606555A4 (fr) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai Anticorps anti-neuraminidase du virus influenza de type b et leurs utilisations
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CA3087239A1 (fr) 2018-02-27 2019-09-06 University Of Rochester Vaccin vivant attenue multivalent contre la grippe pour la prevention et le controle du virus de la grippe equine (eiv) chez les chevaux
CA3104297A1 (fr) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Polypeptides d'hemagglutinines du virus de la grippe en mosaique et leurs utilisations
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
CN113905759A (zh) 2019-02-27 2022-01-07 罗切斯特大学 用于预防和控制马的马流感病毒(eiv)的多价减毒活流感疫苗
US11103576B1 (en) 2020-06-15 2021-08-31 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Measles virus vaccine expressing SARS-COV-2 protein(s)
WO2025019631A1 (fr) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Compositions immunogènes contenant un virus de la grippe a inactivé et un adjuvant oligonucléotidique cpg et leurs utilisations
WO2025080985A1 (fr) 2023-10-13 2025-04-17 Flagship Pioneering Innovations V, Inc. Distribution d'anellovecteur spécifique à un tissu
WO2025160409A1 (fr) 2024-01-26 2025-07-31 Flagship Pioneering Innovations V, Inc. Vecteurs viraux pour moduler la fonction vegf

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0440219A1 (fr) * 1990-02-02 1991-08-07 SCHWEIZERISCHES SERUM- & IMPFINSTITUT BERN ADNc correspondant au génome des virus à ARN "brin-négatifs" et procédé pour la production de virus à ARN "brin-négatifs" infectieux
EP0540135A2 (fr) * 1991-10-14 1993-05-05 The Kitasato Institute Souche attenuée vaccinale du virus de la rougeole, contenant une séquence nucléotidique spécifique et procédé pour son identification absolue
EP0567100A1 (fr) * 1992-04-21 1993-10-27 American Cyanamid Company Virus syncytial respiratoire (RSV) mutant, vaccins le contenant et méthodes d'utilisation
WO1993021306A1 (fr) * 1992-04-14 1993-10-28 The Mount Sinai School Of Medicine Of The City University Of New York Virus attenues par genie genetique
WO1993021310A1 (fr) * 1992-04-21 1993-10-28 American Home Products Corporation Compositions de vaccins a base de virus respiratoire syncytial attenue
EP0702085A1 (fr) * 1994-07-18 1996-03-20 Akzo Nobel N.V. Virus ARN récombinant, infectieux, non-segmenté, brin-négatif

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0440219A1 (fr) * 1990-02-02 1991-08-07 SCHWEIZERISCHES SERUM- & IMPFINSTITUT BERN ADNc correspondant au génome des virus à ARN "brin-négatifs" et procédé pour la production de virus à ARN "brin-négatifs" infectieux
EP0540135A2 (fr) * 1991-10-14 1993-05-05 The Kitasato Institute Souche attenuée vaccinale du virus de la rougeole, contenant une séquence nucléotidique spécifique et procédé pour son identification absolue
WO1993021306A1 (fr) * 1992-04-14 1993-10-28 The Mount Sinai School Of Medicine Of The City University Of New York Virus attenues par genie genetique
EP0567100A1 (fr) * 1992-04-21 1993-10-27 American Cyanamid Company Virus syncytial respiratoire (RSV) mutant, vaccins le contenant et méthodes d'utilisation
WO1993021310A1 (fr) * 1992-04-21 1993-10-28 American Home Products Corporation Compositions de vaccins a base de virus respiratoire syncytial attenue
EP0702085A1 (fr) * 1994-07-18 1996-03-20 Akzo Nobel N.V. Virus ARN récombinant, infectieux, non-segmenté, brin-négatif

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
COLLINS P.L. ET AL.: "Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development.", PROC. NATL. ACAD. SCI. USA, vol. 92, December 1995 (1995-12-01), pages 11563 - 11567, XP002066592 *
CROWE J.E. ET AL.: "Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene.", VIRUS GENES, vol. 13, no. 3, February 1996 (1996-02-01), pages 269 - 273, XP002066591 *
MORI T. ET AL.: "Molecular cloning and complete nucleotide sequence of genomic RNA of the AIK-C strain of attenuated measles virus.", VIRUS GENES, vol. 7, no. 1, 1993, pages 67 - 81, XP002051752 *
RADECKE F. ET AL.: "RESCUE OF MEASLES VIRUSES FROM CLONED DNA", EMBO JOURNAL, vol. 14, no. 23, 1 December 1995 (1995-12-01), pages 5773 - 5784, XP002022952 *
STOKES A. ET AL.: "The complete nucleotide sequence of two cold-adapted, temperature-sensitive attenuated mutant vaccine viruses(cp12 and cp45) derived from the JS strain of human parainfluenza virus type 3 (PIV3).", VIRUS RESEARCH, vol. 30, 1993, pages 43 - 52, XP002051711 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12391957B2 (en) 2018-08-17 2025-08-19 Icahn School Of Medicine At Mount Sinai Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease

Also Published As

Publication number Publication date
WO1998013501A2 (fr) 1998-04-02
JP2000517194A (ja) 2000-12-26
BR9712138A (pt) 2000-01-18
CN1232504A (zh) 1999-10-20
CA2265554A1 (fr) 1998-04-02
EP0932684A2 (fr) 1999-08-04
KR20000048628A (ko) 2000-07-25
AU4427897A (en) 1998-04-17

Similar Documents

Publication Publication Date Title
WO1998013501A3 (fr) Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
FR2712603B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2716893B1 (fr) Virus recombinants, leur préparation et leur utilisation thérapeutique.
CA2011878A1 (fr) Regions immunogenes sur la proteine e7 du papillomavirus humain de type 16
EP1128832A4 (fr) Composes, compositions et procedes pour traiter des infections virales et les maladies qui y sont liees
WO2004014314A3 (fr) Procedes et compositions concernant les poxvirus et le cancer
WO1995032298A3 (fr) Vecteurs surs pour therapie genique
WO2001068103A3 (fr) Methode pouvant ameliorer les symptomes d'une infection herpetique au moyen de sequences polynucleotidiques immunomodulatrices
FI971272A7 (fi) Heikennetty rokotus- ja geenisiirtovirus, menetelmä viruksen valmista miseksi ja virusta sisältävä farmaseuttinen koostumus
FR2718150B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
CA2186044A1 (fr) Nouveaux virus mutes, composes antiviraux et nouveaux procedes de production de vaccins
CA2113089A1 (fr) Cellules donneuses universelles
GB9306731D0 (en) Vaccines
DE69500618D1 (de) Oligonukleotide mit wirkung gegen das respiratorische synzytial virus
FR2712602B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
ZA964679B (en) Genetically altered feline immunodeficiency viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
CA2278808A1 (fr) Procedes pour la culture de cellules et la multiplication de virus
BR9815285A (pt) Vetores alfavìrus para vacina de paramixovìrus
CA2329510A1 (fr) Sequences de type promoteur exprimees dans les antheres et les pollens
WO2001077358A3 (fr) Virus de l'herpes destines a l'immunomodulation
WO2000034445A3 (fr) Vaccin vivant attenue de l'encephalomyelite equine du venezuela
AU4425397A (en) Antisense gene therapy for rna viruses
CA2066998A1 (fr) Virus de la varicella-zona recombinant et procede de construction
FR2717495B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97198321.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK SL TJ TM TR TT UA UG US UZ VN ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997942613

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2265554

Country of ref document: CA

Ref document number: 2265554

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09269367

Country of ref document: US

ENP Entry into the national phase

Ref document number: 1998 515749

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019997002569

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1997942613

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997002569

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997942613

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019997002569

Country of ref document: KR